Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Small Pharma Inc (OP: DMTTF ) N/A UNCHANGED Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Small Pharma Inc < Previous 1 2 Next > InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector October 23, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics October 23, 2023 From Cybin Inc. Via Business Wire Small Pharma Reports Fiscal Second Quarter 2024 Highlights October 19, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Obtains Final Order Approving Arrangement October 17, 2023 From Cybin Inc. Via Business Wire Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders October 12, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder September 26, 2023 From Small Pharma Inc. Via GlobeNewswire Cybin to Acquire Small Pharma Inc. August 28, 2023 - All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for... Via Newsfile Topics Intellectual Property Exposures Intellectual Property InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’ August 28, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Cybin to Acquire Small Pharma Inc. August 28, 2023 From Cybin Inc. Via Business Wire Small Pharma Reports Fiscal First Quarter 2024 Highlights July 27, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Announces SPL028 R&D Strategy Update July 05, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Announces Management Team Change July 05, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights June 28, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Announces Significant Developments In Intellectual Property Portfolio May 25, 2023 5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions From Small Pharma Inc. Via GlobeNewswire Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology May 03, 2023 Chief Medical and Scientific Officer, Dr. Carol Routledge, will deliver a poster presentation on data from the Company’s SPL026 Phase IIa clinical trial in patients with Major Depressive Disorder From Small Pharma Inc. Via GlobeNewswire Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026 April 04, 2023 Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months From Small Pharma Inc. Via GlobeNewswire Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry March 07, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results March 07, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference March 01, 2023 Company will also host a cocktail reception on Tuesday, March 7 From Small Pharma Inc. Via GlobeNewswire First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028 February 15, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue February 01, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Reports Fiscal Third Quarter 2023 Highlights January 25, 2023 Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental Via PressReach Small Pharma Reports Fiscal Third Quarter 2023 Highlights January 25, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder January 25, 2023 From Small Pharma Inc. Via GlobeNewswire Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25 January 24, 2023 From Small Pharma Inc. Via GlobeNewswire First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026 January 09, 2023 Study will compare the profile of intramuscular versus intravenous SPL026 administration From Small Pharma Inc. Via GlobeNewswire Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property December 22, 2022 From Small Pharma Inc. Via GlobeNewswire First Patient Dosed in Small Pharma’s Drug Interaction Study December 15, 2022 Open-label study will assess the interaction between SSRI antidepressants and SPL026 From Small Pharma Inc. Via GlobeNewswire Small Pharma To Support University College London Research Project on Neuroplasticity December 14, 2022 Small Pharma will provide SPL026 for the brain-imaging study, which seeks to explore how psychedelic-induced brain changes impact cognition, behaviour and well-being From Small Pharma Inc. Via GlobeNewswire Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium December 08, 2022 From Small Pharma Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
